[go: up one dir, main page]

SI1965823T1 - Postopki za dajanje hipoglikemičnih sredstev - Google Patents

Postopki za dajanje hipoglikemičnih sredstev

Info

Publication number
SI1965823T1
SI1965823T1 SI200632086A SI200632086A SI1965823T1 SI 1965823 T1 SI1965823 T1 SI 1965823T1 SI 200632086 A SI200632086 A SI 200632086A SI 200632086 A SI200632086 A SI 200632086A SI 1965823 T1 SI1965823 T1 SI 1965823T1
Authority
SI
Slovenia
Prior art keywords
methods
hypoglycemic agents
administering
administering hypoglycemic
agents
Prior art date
Application number
SI200632086A
Other languages
English (en)
Inventor
Mark A. Bush
Mary Colleen O'neill
Original Assignee
Glaxosmithkline Llc Corporation Service Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38024051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1965823(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc Corporation Service Company filed Critical Glaxosmithkline Llc Corporation Service Company
Publication of SI1965823T1 publication Critical patent/SI1965823T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
SI200632086A 2005-11-04 2006-11-03 Postopki za dajanje hipoglikemičnih sredstev SI1965823T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73392005P 2005-11-04 2005-11-04
US74260005P 2005-12-06 2005-12-06
PCT/US2006/060508 WO2007056681A2 (en) 2005-11-04 2006-11-03 Methods for administering hypoglycemic agents
EP06839697.7A EP1965823B1 (en) 2005-11-04 2006-11-03 Methods for administering hypoglycemic agents

Publications (1)

Publication Number Publication Date
SI1965823T1 true SI1965823T1 (sl) 2016-09-30

Family

ID=38024051

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200632086A SI1965823T1 (sl) 2005-11-04 2006-11-03 Postopki za dajanje hipoglikemičnih sredstev

Country Status (13)

Country Link
US (4) US8202837B2 (sl)
EP (2) EP1965823B1 (sl)
JP (2) JP2009514900A (sl)
CY (1) CY1118007T1 (sl)
DK (1) DK1965823T3 (sl)
ES (1) ES2586236T3 (sl)
HR (1) HRP20160866T1 (sl)
HU (2) HUE029798T2 (sl)
LT (2) LT1965823T (sl)
PL (1) PL1965823T3 (sl)
PT (1) PT1965823T (sl)
SI (1) SI1965823T1 (sl)
WO (1) WO2007056681A2 (sl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260259A1 (en) 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
ATE494010T1 (de) 2002-02-27 2011-01-15 Pharmain Corp Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
ES2586236T3 (es) 2005-11-04 2016-10-13 Glaxosmithkline Llc Procedimientos para administrar agentes hipoglucémicos
WO2007076371A2 (en) 2005-12-19 2007-07-05 Pharmain Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
DK2020990T3 (da) 2006-05-30 2010-12-13 Intarcia Therapeutics Inc Strømningsmodulator med en indre kanal til et todelt osmotisk fremføringssystem
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
PE20080840A1 (es) * 2006-09-13 2008-08-27 Smithkline Beecham Corp Metodos para administrar agentes hipoglucemiantes de larga duracion
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
WO2008154619A1 (en) 2007-06-12 2008-12-18 Smithkline Beecham Corporation Methods for detecting protein in plasma
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
JP2012511586A (ja) * 2008-12-10 2012-05-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 医薬組成物
WO2011037623A1 (en) 2009-09-28 2011-03-31 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US8691763B2 (en) 2010-05-04 2014-04-08 Glaxosmithkline Llc Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
DK2672986T3 (da) 2011-02-09 2020-06-08 Glaxosmithkline Llc Frysetørrede formuleringer
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
SG11201504771RA (en) * 2013-03-06 2015-09-29 Glaxosmithkline Llc Host cells and methods of use
EP2976325B1 (en) 2013-03-21 2017-03-01 Sanofi-Aventis Deutschland GmbH Synthesis of cyclic imide containing peptide products
WO2014147124A1 (en) 2013-03-21 2014-09-25 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
CA3024479A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
CN117241821B (zh) * 2022-03-25 2024-04-09 北京质肽生物医药科技有限公司 多肽缀合物的药物组合物及其使用方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313439A (en) 1980-03-24 1982-02-02 Biotek, Inc. Automated, spring-powered medicament infusion system
US4790824A (en) * 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DK134691D0 (da) 1991-07-12 1991-07-12 Novo Nordisk As Apparat
US5536249A (en) * 1994-03-09 1996-07-16 Visionary Medical Products, Inc. Pen-type injector with a microprocessor and blood characteristic monitor
US6629963B2 (en) * 1996-06-20 2003-10-07 Becton, Dickinson And Company Syringe and needle shield assembly and method of sterilizing such assembly
US6146361A (en) * 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
BR9913284A (pt) * 1998-08-28 2001-05-15 Lilly Co Eli Métodos para administrar peptìdeos insulinotrópicos
US20030087820A1 (en) * 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
US6569143B2 (en) * 1999-10-14 2003-05-27 Becton, Dickinson And Company Method of intradermally injecting substances
US6776776B2 (en) * 1999-10-14 2004-08-17 Becton, Dickinson And Company Prefillable intradermal delivery device
US6843781B2 (en) * 1999-10-14 2005-01-18 Becton, Dickinson And Company Intradermal needle
MXPA03005036A (es) * 2000-12-07 2003-09-05 Lilly Co Eli Proteinas de fusion glp-1.
AU2002239384B2 (en) * 2000-12-13 2007-01-11 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
EP1542712A2 (en) * 2001-06-01 2005-06-22 Eli Lilly And Company Glp-1 formulations with protracted time action
CN1363654A (zh) * 2001-07-19 2002-08-14 上海华谊生物技术有限公司 生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法
US7235063B2 (en) * 2001-08-21 2007-06-26 D'antonio Consultants International, Inc. Hypodermic injection system
CA2458371A1 (en) * 2001-08-23 2003-03-06 Eli Lilly And Company Glucagon-like peptide-1 analogs
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
EP1585959A4 (en) * 2002-01-08 2007-11-14 Lilly Co Eli PEPTIDE-1 ANALOGUES OF EXTENSION GLUCAGON TYPE
TWI314464B (en) 2002-06-24 2009-09-11 Alza Corp Reusable, spring driven autoinjector
AU2003277446A1 (en) * 2002-10-17 2004-05-04 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
DK2526996T3 (da) 2002-12-20 2019-12-02 Xeris Pharmaceuticals Inc Formulering til intrakutan injektion
NZ554885A (en) * 2002-12-31 2009-07-31 Altus Pharmaceuticals Inc Complexes of hgh crystals and protamine polymers
EP1594530A4 (en) * 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
EP1592471B1 (en) 2003-02-04 2011-03-23 Novo Nordisk A/S Injection device with rotatable dose setting mechanism
ATE525395T1 (de) 2003-06-12 2011-10-15 Lilly Co Eli Fusions proteine von glp-1-analoga
KR20060109940A (ko) * 2003-12-18 2006-10-23 노보 노르디스크 에이/에스 알부민-유사제에 연결된 신규 ｇｌｐ-1 유사체
EP1729795B1 (en) * 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albumin fusion proteins
DE602005008953D1 (de) * 2004-05-21 2008-09-25 Novartis Vaccines & Diagnostic Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
US7076987B2 (en) * 2004-08-05 2006-07-18 Becton, Dickinson And Company Method of producing tapered or pointed cannula
DK1881850T3 (da) 2005-05-13 2011-01-03 Lilly Co Eli GLP-1-PEGylerede forbindelser
CA2609810C (en) 2005-06-06 2012-05-22 Camurus Ab Glp-1 analogue formulations
ES2586236T3 (es) 2005-11-04 2016-10-13 Glaxosmithkline Llc Procedimientos para administrar agentes hipoglucémicos
PE20080840A1 (es) 2006-09-13 2008-08-27 Smithkline Beecham Corp Metodos para administrar agentes hipoglucemiantes de larga duracion

Also Published As

Publication number Publication date
EP1965823A2 (en) 2008-09-10
PL1965823T3 (pl) 2017-08-31
WO2007056681A2 (en) 2007-05-18
EP3095456A1 (en) 2016-11-23
JP2009514900A (ja) 2009-04-09
HUS1600047I1 (hu) 2017-01-30
LT1965823T (lt) 2016-10-10
HRP20160866T1 (hr) 2016-10-07
DK1965823T3 (en) 2016-08-22
LTPA2016032I1 (lt) 2016-12-12
CY1118007T1 (el) 2017-05-17
WO2007056681A3 (en) 2008-04-10
US20130225489A1 (en) 2013-08-29
HUE029798T2 (en) 2017-03-28
US20160022781A1 (en) 2016-01-28
EP1965823A4 (en) 2010-08-04
PT1965823T (pt) 2016-08-18
JP2014159431A (ja) 2014-09-04
ES2586236T3 (es) 2016-10-13
EP1965823B1 (en) 2016-05-18
US20080254087A1 (en) 2008-10-16
US8202837B2 (en) 2012-06-19
US20130231282A1 (en) 2013-09-05

Similar Documents

Publication Publication Date Title
HUS1600047I1 (hu) Eljárások hipoglikémiás szerek beadására
IL189212A0 (en) Therapeutic agent for diabetes
SI3424932T1 (sl) Boronoftalidi za terapevtsko uporabo
ZA200706622B (en) Microimplants for ocular administration
IL192369A0 (en) Therapeutic agent for diabetes
IL197448A0 (en) Methods for administering long-lasting hypoglycemic agents
GB0506147D0 (en) Therapeutic agents
GB0519797D0 (en) Therapeutic agents
GB0505437D0 (en) Therapeutic agents
GB0505725D0 (en) Therapeutic agents
GB0518819D0 (en) Therapeutic agents
GB0519350D0 (en) Therapeutic agents
GB0518817D0 (en) Therapeutic agents
GB0514738D0 (en) Therapeutic agents
GB0516661D0 (en) Therapeutic agents
GB0523998D0 (en) Therapeutic agents
GB0522433D0 (en) Therapeutic agents
HK1130007A (en) Methods for administering long-lasting hypoglycemic agents
ZA200806143B (en) Therapeutic agent for diabetes
GB0502541D0 (en) Medicament
GB0513208D0 (en) Therapeutic agents
GB0511903D0 (en) Therapeutic agents
GB0525124D0 (en) Therapeutic agents
GB0521538D0 (en) Therapeutic agents
GB0516496D0 (en) Therapeutic agents